Iron metabolism and iron disorders revisited in the hepcidin era

Clara Camaschella,Antonella Nai,Laura Silvestri

DOI: https://doi.org/10.3324/haematol.2019.232124

2020-01-16

Haematologica

Abstract:Iron is biologically essential, but also potentially toxic; as such it is tightly controlled at cell and systemic level to prevent both deficiency and overload. Iron Regulatory Proteins post-transcriptionally control genes encoding proteins that modulate iron uptake, recycling and storage and are themselves regulated by iron. The master regulator of systemic iron homeostasis is the liver peptide hepcidin, which controls serum iron through degradation of ferroportin in iron absorptive enterocytes and iron recycling macrophages. This review emphasizes the most recent results in the field of iron biology, the deregulation of the hepcidin-ferroportin axis in iron disorders and how research results impact on clinical disorders. Insufficient hepcidin production is central to iron overload while hepcidin excess lead to iron restriction. Mutations of hemochromatosis genes result in iron excess by downregulating the liver BMP/SMAD signaling pathway. In iron loading anemias as β-thalassemia an enhanced albeit ineffective erythropoiesis releases erythroferrone that sequesters the BMP receptor ligand BMPs, thereby inhibiting hepcidin. In Iron-Refractory Iron-Deficiency Anemia mutations of the hepcidin inhibitor TMPRSS6 upregulates the BMP/SMAD pathway. Interleukin-6 in acute and chronic inflammation, increases hepcidin levels causing iron-restricted erythropoiesis and anemia of inflammation in the presence of iron replete macrophages. Our improved understanding of iron homeostasis and its regulation is impacting on the established schedules of oral iron treatment and the choice of oral vs intravenous iron in iron deficiency. Moreover it is leading to the development of targeted therapies for iron overload and inflammation, mainly centered on the manipulation of the hepcidin-ferroportin axis.

hematology